Moderna says COVID-19 vaccine protection wanes, makes case for booster

Moderna says COVID-19 vaccine protection wanes, makes case for booster
CHICAGO -- New data from Moderna s large COVID-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release on Wednesday.

"This is only one estimate, but we do believe this means as you look toward the fall and winter, at minimum we expect the estimated impact of waning immunity would be 600,000 additional cases of COVID-19," Moderna President Stephen Hoge said on a conference call with investors.

Hoge did not project how many of the cases would be severe, but said some would require hospitalization.

The data stands in stark contrast with data from several recent studies that suggested Moderna s vaccine protection lasts longer than a similar shot from Pfizer Inc and German partner BioNTech SE.

Experts said the difference is likely due to Moderna s higher dose of messenger RNA (mRNA) and the slightly longer interval between the first and second shots.

Both vaccines proved to be exceedingly effective at preventing illness in their large Phase III studies.

Wednesday s analysis, however, showed higher rates of infection among people vaccinated roughly 13 months ago compared with those vaccinated roughly eight months ago. The study period was from July-August, when Delta was the predominant strain. It has yet to undergo peer review.

Moderna on Sept. 1 submitted its application to the U.S. Food and Drug Administration seeking authorization for a booster shot.

Hoge said data from its booster studies shows the vaccine could increase neutralizing antibodies to levels even higher than were seen after the second dose.

"We believe this will reduce COVID-19 cases," he said. "We also believe that a third dose of mRNA-1273 has a chance of significantly extending immunity throughout much of next year as we attempt to end the pandemic."

Briefing documents from the FDA s analysis of Pfizer s booster application, released earlier on Wednesday, suggest that a key issue the agency will consider is whether vaccine protection is waning.

In its analysis, Moderna compared the vaccine s performance in more than 14,000 volunteers vaccinated between July and October of 2020 with some 11,000 volunteers originally in the placebo group who were offered the shot between December 2020 and March 2021 following its U.S. emergency use authorization.

In the two-month period from July-August, researchers identified 88 COVID-19 cases among those who got the two shots more recently, compared with 162 cases among those vaccinated last year. Overall, only 19 cases were considered severe, a key benchmark in assessing waning protection.

Moderna said there was a trend toward a lower rate of severe cases among the more recently vaccinated, although the finding was not statistically significant.

Data from a separate study presented on Wednesday conducted with Kaiser Permanente Southern California health system, meanwhile, shows that Moderna s vaccine continued to perform well against the Delta variant.

Researchers compared data on more than 352,000 people who got two doses of the Moderna vaccine with the same number of unvaccinated individuals and found the Moderna vaccine was 87% effective at preventing a COVID-19 diagnosis, and 96% effective at preventing hospitalization.

Hoge said the vaccine s initial performance is strong, but argued that protection shouldn t be allowed to wane.
Read more on CTVnews
News Topics :
Similar Articles :
Top Stories
The idea of waning immunity has picked up steam in recent weeks, with some countries using it to justify rolling out third dose COVID 19 vaccine boosters to their populations. But immunologists...
The effectiveness of COVID 19 vaccines for people in American nursing homes and long term care facilities, where residents are often elderly and frail, has dropped since the Delta variant became dominant...
Even as the United States made the controversial announcement this week that it would begin to offer COVID 19 vaccine booster shots in September, scientists and public officials were scrambling to...
Less than 24 hours after the small biotech Novavax announced the largely successful results of its COVID 19 vaccine , a pharmaceutical giant, Johnson & Johnson J&J , said its candidate also...
The U.S. government said on Wednesday it plans to make COVID 19 vaccine booster shots widely available starting on Sept. 20 as infections rise from the coronavirus Delta variant, citing data...